arXiv:2606.05474v1 Announce Type: cross Abstract: Protein binder design has largely optimized for affinity alone, leaving conformational selectivity unaddressed: for allosteric targets such as kinases, nuclear receptors, and GPCRs, a binder that engages both active and inactive states provides no functional specificity regardless of how tightly it binds. We introduce AlloGen, a modular framework that decouples backbone generation from a learned state-selectivity scorer $Q_\theta$, an SE(3)-invariant interface graph transformer trained via a two-phase curriculum that first learns interface geom
Advances in AI, particularly SE(3)-invariant graph transformers, are enabling more sophisticated approaches to drug and binder design, moving beyond brute-force optimization.
This research introduces a novel framework for designing conformation-selective protein binders, addressing a critical limitation in current drug development for complex allosteric targets, potentially leading to more targeted and effective therapeutics.
The ability to generate binders that specifically engage particular protein states, rather than just binding affinity, offers a new paradigm for developing drugs against previously 'undruggable' targets.
- · Pharmaceutical companies
- · Biotech startups
- · Patients with complex diseases
- · AI-driven drug discovery platforms
- · Traditional drug discovery methods
- · Companies reliant on broad-spectrum binders
More effective and fewer off-target therapies for allosteric diseases become feasible.
The cost and timeline for developing certain classes of drugs could decrease significantly as design becomes more precise.
This could enable entirely new therapeutic modalities and targets, accelerating the synthetic biology revolution in medicine.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG